<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565576</url>
  </required_header>
  <id_info>
    <org_study_id>CCFZ533X2204</org_study_id>
    <nct_id>NCT02565576</nct_id>
  </id_info>
  <brief_title>Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability,
      pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of
      care in patients with moderate to severe myasthenia gravis (MG).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2015</start_date>
  <completion_date type="Actual">December 19, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in the Quantitative Myastenia Gravis (QMG) score</measure>
    <time_frame>At week 25</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean changes from baseline in the MGC score</measure>
    <time_frame>From baseline to week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement or worsening by ≥ 3 points in the QMG score</measure>
    <time_frame>From baseline to week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients intolerant to steroid taper</measure>
    <time_frame>from week 13 to week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who discontinued due to inefficacy or worsening</measure>
    <time_frame>from baseline to week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the Myasthenia Gravis-specific Activities of Daily Living scale (MG-ADL)</measure>
    <time_frame>From baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes from baseline in the QMG score</measure>
    <time_frame>From baseline to week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the Myasthenia Gravis Quality of Life (MG QOL-15)</measure>
    <time_frame>From baseline to week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Myasthenia Gravis, Generalized</condition>
  <arm_group>
    <arm_group_label>CFZ533</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CFZ533</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>CFZ533</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533</intervention_name>
    <arm_group_label>CFZ533</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of MG class IIa to IVa inclusive (Myasthenia Gravis Foundation of America
             Clinical Classification).

          2. Quantitative Myasthenia Gravis (QMG) score of 10 or greater. If the QMG score is &lt; 15
             no more than 4 points may be derived from items 1 or 2 (ocular motility disturbance
             and ptosis).

          3. Documented history of acetylcholine receptor (AChR) or Muscle Specific Kinase (MuSK)
             antibody positive.

          4. Only one immunosuppressant or immunomodulatory drug at a stable dose is allowed during
             the study (i) azathioprine and mycophenolate mofetil must be stable for at least 4
             months prior to randomization (ii) cyclosporine must be stable for at least 3 months
             prior to randomization.

          5. If the patient is on oral corticosteroids, methotrexate or tacrolimus at screening,
             the dose must be stable for at least 1 month prior to randomization.

          6. If the patient is on cholinesterase inhibitors at screening, the dose must be stable
             for at least 2 weeks prior to randomization.

          7. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, may be included in the study if they are using highly effective
             methods of contraception during the study and for 12 weeks after study treatment.

        Exclusion Criteria:

          1. MGFA grade I, IVb, or V disease.

          2. Documented presence of unresected thymoma.

          3. Patients having undergone thymectomy or thymo thymectomy (resection of thymoma) within
             6 months of screening.

          4. Patients having received any of the following treatments prior to randomization:

               1. IVIg or plasma exchange within 8 weeks;

               2. oral or IV cyclosphosphamide treatment within 3 months;

               3. IV corticosteroid bolus (dose higher than 1 mg/kg) within 3 months;

               4. belimumab within 6 months. For patients who received belimumab earlier, B cell
                  count should be within normal range;

               5. rituximab within 12 months. For patients who received rituximab earlier, B cell
                  count should be within normal range;

               6. any other biologic or an investigational drug within 1 month or five times
                  thehalf-life, whichever is longer.

               7. Live vaccines within 4 weeks of study drug infusion.

          5. Patients who are at significant risk for TE as judged by the investigator or have any
             one of the following:

               1. History of either thrombosis or 3 or more spontaneous abortions with or without
                  the presence of anti-cardiolipin autoantibodies;

               2. Presence of prolonged partial thromboplastin time (PTT).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2BA</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Samara</city>
        <state>Samara Region</state>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>S-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <state>Taiwan ROC</state>
        <zip>70421</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CFZ533, Myasthenia Gravis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

